Strs Ohio Makes New $136,000 Investment in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Strs Ohio acquired a new position in LeMaitre Vascular, Inc. (NASDAQ:LMATGet Rating) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 2,700 shares of the medical instruments supplier’s stock, valued at approximately $136,000.

A number of other institutional investors and hedge funds have also made changes to their positions in LMAT. Citigroup Inc. grew its stake in shares of LeMaitre Vascular by 6.6% in the 1st quarter. Citigroup Inc. now owns 20,987 shares of the medical instruments supplier’s stock worth $975,000 after buying an additional 1,293 shares in the last quarter. MetLife Investment Management LLC grew its stake in shares of LeMaitre Vascular by 58.0% in the 1st quarter. MetLife Investment Management LLC now owns 12,092 shares of the medical instruments supplier’s stock worth $562,000 after buying an additional 4,441 shares in the last quarter. Rhumbline Advisers grew its stake in shares of LeMaitre Vascular by 8.2% in the 1st quarter. Rhumbline Advisers now owns 95,806 shares of the medical instruments supplier’s stock worth $4,452,000 after buying an additional 7,266 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in shares of LeMaitre Vascular by 14.1% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 16,567 shares of the medical instruments supplier’s stock worth $770,000 after buying an additional 2,042 shares in the last quarter. Finally, BlackRock Inc. grew its stake in shares of LeMaitre Vascular by 0.9% in the 1st quarter. BlackRock Inc. now owns 3,175,432 shares of the medical instruments supplier’s stock worth $147,562,000 after buying an additional 28,008 shares in the last quarter. 86.85% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, Director John A. Roush sold 7,500 shares of the business’s stock in a transaction dated Thursday, December 1st. The shares were sold at an average price of $46.65, for a total value of $349,875.00. Following the completion of the sale, the director now directly owns 8,076 shares of the company’s stock, valued at approximately $376,745.40. The transaction was disclosed in a filing with the SEC, which is available through this link. 12.50% of the stock is owned by corporate insiders.

LeMaitre Vascular Trading Up 1.2 %

LMAT stock opened at $47.16 on Friday. LeMaitre Vascular, Inc. has a 12 month low of $38.32 and a 12 month high of $56.38. The company has a 50-day moving average price of $45.94 and a 200 day moving average price of $48.13. The stock has a market cap of $1.04 billion, a PE ratio of 49.13, a P/E/G ratio of 3.90 and a beta of 1.01.

LeMaitre Vascular (NASDAQ:LMATGet Rating) last released its quarterly earnings results on Thursday, October 27th. The medical instruments supplier reported $0.25 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.03). The firm had revenue of $39.03 million for the quarter, compared to analysts’ expectations of $40.13 million. LeMaitre Vascular had a return on equity of 9.33% and a net margin of 13.22%. Sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.08 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 1st. Shareholders of record on Thursday, November 17th were given a $0.125 dividend. The ex-dividend date was Wednesday, November 16th. This represents a $0.50 annualized dividend and a yield of 1.06%. LeMaitre Vascular’s dividend payout ratio (DPR) is 52.08%.

Analyst Ratings Changes

LMAT has been the subject of a number of recent analyst reports. StockNews.com raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Monday, December 5th. Barrington Research cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, October 28th.

LeMaitre Vascular Profile

(Get Rating)

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system.

Recommended Stories

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMATGet Rating).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.